Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial von Motzer, Robert J, Rini, Brian I, McDermott, David F, Redman, Bruce G, Kuzel, Timothy M, Harrison, Michael R, Vaishampayan, Ulka N, Drabkin, Harry A, George, Saby, Logan, Theodore F, Margolin, Kim A, Plimack, Elizabeth R, Lambert, Alexandre M, Waxman, Ian M, Hammers, Hans J

Volltext

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma von Escudier, Bernard, Sharma, Padmanee, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Gurney, Howard, Donskov, Frede, Peltola, Katriina, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Zhao, Huanyu, Waxman, Ian M, Motzer, Robert J

Volltext

Adolescent non‐Hodgkin lymphoma and Hodgkin lymphoma: state of the science von Hochberg, Jessica, Waxman, Ian M., Kelly, Kara M., Morris, Erin, Cairo, Mitchell S.

Volltext

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma von Weber, Jeffrey S, Hodi, F Stephen, Wolchok, Jedd D, Topalian, Suzanne L, Schadendorf, Dirk, Larkin, James, Sznol, Mario, Long, Georgina V, Li, Hewei, Waxman, Ian M, Jiang, Joel, Robert, Caroline

Volltext

Nivolumab in Previously Untreated Melanoma without BRAF Mutation von Robert, Caroline, Long, Georgina V, Brady, Benjamin, Dutriaux, Caroline, Maio, Michele, Mortier, Laurent, Hassel, Jessica C, Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Savage, Kerry J, Hernberg, Micaela M, Lebbé, Celeste, Charles, Julie, Mihalcioiu, Catalin, Chiarion-Sileni, Vanna, Mauch, Cornelia, Cognetti, Francesco, Arance, Ana, Schmidt, Henrik, Schadendorf, Dirk, Gogas, Helen, Lundgren-Eriksson, Lotta, Horak, Christine, Sharkey, Brian, Waxman, Ian M, Atkinson, Victoria, Ascierto, Paolo A

Volltext

Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors von Agrawal, Shruti, Statkevich, Paul, Bajaj, Gaurav, Feng, Yan, Saeger, Sally, Desai, Dharmesh D., Park, Jong‐Soon, Waxman, Ian M., Roy, Amit, Gupta, Manish

Volltext

Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy von Gerrard, Mary, Waxman, Ian M., Sposto, Richard, Auperin, Anne, Perkins, Sherrie L., Goldman, Stanton, Harrison, Lauren, Pinkerton, Ross, McCarthy, Keith, Raphael, Martine, Patte, Catherine, Cairo, Mitchell S.

Volltext

Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2... von Escudier, Bernard, Sharma, Padmanee, McDermott, David F., George, Saby, Hammers, Hans J., Srinivas, Sandhya, Tykodi, Scott S., Sosman, Jeffrey A., Procopio, Giuseppe, Plimack, Elizabeth R., Castellano, Daniel, Gurney, Howard, Donskov, Frede, Peltola, Katriina, Wagstaff, John, Gauler, Thomas C., Ueda, Takeshi, Zhao, Huanyu, Waxman, Ian M., Motzer, Robert J.

Volltext

P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153: Track: Immunotherapy von Waterhouse, David, Horn, Leora, Reynolds, Craig, Spigel, David, Chandler, Jason, Mekhail, Tarek, Mohamed, Mohamed, Creelan, Ben, Blankstein, Kenneth B., Nikolinakos, Petros, Mccleod, Michael J., Li, Ang, Waxman, Ian M., Aanur, Nivedita, Agrawal, Shruti, Richardet, Eduardo

Volltext

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma von Long, Georgina V, Atkinson, Victoria, Ascierto, Paolo A, Brady, Benjamin, Dutriaux, Caroline, Maio, Michele, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Savage, Kerry J., Hernberg, Micaela, Lebbé, Celeste, Charles, Julie, Mihalcioiu, Catalin, Chiarion-Sileni, Vanna, Mauch, Cornelia, Schmidt, Henrik, Schadendorf, Dirk, Gogas, Helen, Horak, Christine, Sharkey, Brian, Waxman, Ian M., Robert, Caroline

Volltext

Epoeitin alfa use in children undergoing myelosuppressive chemotherapy von Waxman, Ian M

Volltext

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma von Motzer, Robert J, Escudier, Bernard, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Choueiri, Toni K, Gurney, Howard, Donskov, Frede, Bono, Petri, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Tomita, Yoshihiko, Schutz, Fabio A, Kollmannsberger, Christian, Larkin, James, Ravaud, Alain, Simon, Jason S, Xu, Li-An, Waxman, Ian M, Sharma, Padmanee

Volltext

Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning von Waxman, Ian M., Militano, Olga, Baldinger, Leah, Roman, Elizabeth, Qualter, Erin, Morris, Erin, Garvin, James, Bradley, Mary Brigid, Bhatia, Monica, Satwani, Prakash, George, Diane, Del Toro, Gustavo, Hawks, Ria, Wolownik, Karen, Foley, Sandra, Cheung, Ying-Kuen, Schwartz, Joseph, Van De Ven, Carmella, Baxter-Lowe, Lee Ann, Cairo, Mitchell S.

Volltext

Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study von Motzer, Robert J., Sharma, Padmanee, Escudier, Bernard J., McDermott, David F., George, Saby, Srinivas, Sandy, Tykodi, Scott S., Sosman, Jeffrey Alan, Plimack, Elizabeth R., Nathan, Paul D., Gruenwald, Viktor, Tomita, Yoshihiko, Zhao, Huanyu, Waxman, Ian M., Hammers, Hans J.

Volltext

Safety profile of nivolumab administered as 30-minute (min) infusion: Analysis of data from CheckMate 153 von Waterhouse, David Michael, Horn, Leora, Reynolds, Craig H., Spigel, David R., Chandler, Jason Claud, Mekhail, Tarek, Mohamed, Mohamed K., Creelan, Ben C., Blankstein, Kenneth Bruce, Nikolinakos, Petros, McCleod, Michael, Li, Ang, Waxman, Ian M., Aanur, Nivedita, Agrawal, Shruti

Volltext

P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153 von Waterhouse, David, Horn, Leora, Reynolds, Craig, Spigel, David, Chandler, Jason, Mekhail, Tarek, Mohamed, Mohamed, Creelan, Ben, Blankstein, Kenneth B., Nikolinakos, Petros, Mccleod, Michael J., Li, Ang, Waxman, Ian M., Aanur, Nivedita, Agrawal, Shruti, Richardet, Eduardo

Volltext

Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies von McDermott, David F., Motzer, Robert J., Atkins, Michael B., Plimack, Elizabeth R., Sznol, Mario, George, Saby, Drake, Charles G., Rini, Brian I., Choueiri, Toni K., Kuzel, Timothy, Sosman, Jeffrey Alan, Smith, David C., Vaishampayan, Ulka N., Powderly, John D., Topalian, Suzanne Louise, Zhao, Huanyu, Waxman, Ian M., Hammers, Hans J.

Volltext

CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) von Motzer, Robert J., Sharma, Padmanee, McDermott, David F., George, Saby, Hammers, Hans J., Srinivas, Sandhya, Tykodi, Scott S., Sosman, Jeffrey Alan, Procopio, Giuseppe, Plimack, Elizabeth R., Castellano, Daniel E., Gurney, Howard, Donskov, Frede, Bono, Petri, Wagstaff, John, Gauler, Thomas Christoph, Ueda, Takeshi, Zhao, Huanyu, Waxman, Ian M, Escudier, Bernard

Volltext

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma von Motzer, Robert J, Escudier, Bernard, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Choueiri, Toni K, Gurney, Howard, Donskov, Frede, Bono, Petri, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Tomita, Yoshihiko, Schutz, Fabio A, Kollmannsberger, Christian, Larkin, James, Ravaud, Alain, Simon, Jason S, Xu, Li-An, Waxman, Ian M, Sharma, Padmanee, CheckMate 025 Investigators

Volltext

Nivolumab versus everolimus in advanced renal-cell carcinoma von Motzer, Robert J, Escudier, Bernard, McDermott, David F, George, Saby, Hammers, Hans J, Srinivas, Sandhya, Tykodi, Scott S, Sosman, Jeffrey A, Procopio, Giuseppe, Plimack, Elizabeth R, Castellano, Daniel, Choueiri, Toni K, Gurney, Howard, Donskov, Frede, Bono, Petri, Wagstaff, John, Gauler, Thomas C, Ueda, Takeshi, Tomita, Yoshihiko, Schutz, Fabio A, Kollmannsberger, Christian, Larkin, James, Ravaud, Alain, Simon, Jason S, Xu, Li-An, Waxman, Ian M, Sharma, Padmanee, CheckMate 025 Investigators, [missing], Rottey, Sylvie

Volltext